Astera Labs (ALAB) Stock Plummets After AMD-Oracle AI Deal – What Investors Should Know

Astera Labs (ALAB) Stock Plummets After AMD-Oracle AI Deal – What Investors Should Know

  • Stock price: $161.55 (Oct 15 close), down ~19% from $199.53 on Oct 13; volume ~17.3M; market cap ~$26.9B Investing Investing.
  • Catalyst: AMD’s Oct 14 announcement of a 50,000-GPU deployment deal with Oracle sent ALAB tumbling ~19% Tipranks. Investors fear tighter AMD-cloud integrations could cut into Astera’s PCIe connectivity business Gurufocus.
  • Analyst outlook: Consensus remains bullish – 14 buys vs 4 holds, avg. price target ~$187 (≈+16% upside) Tipranks. Citi reiterated a Buy (street-high $275 PT) citing Astera as a leader in “open AI networking” Finviz. BofA (Neutral, $230 PT) notes the AI infrastructure race is “intensifying” but Astera is “well positioned” for demand in PCIe/UALink chips Tipranks.
  • Earnings & guidance: Q2 2025 revenue was $191.9M (+150% YoY) with EPS $0.44 Finviz. Record cash flow and a $1.07B cash balance were reported. Q3 revenue is guided ~$203–210M Finviz (6–9% sequential growth), driven by volume production of its new PCIe 6 “Scorpio” switches.
  • Partnerships & tech: Astera is emphasizing open-standard AI connectivity. At the Oct 13 OCP Summit it showcased rack-scale demos (PCIe, UALink, CXL, Ethernet) and broad collaborations (GPUs, CPUs, cables, ODMs, management software) Nasdaq Nasdaq. On Oct 14 it joined Arm’s Total Design ecosystem to integrate its connectivity platform with Arm’s Neoverse CPUs Finviz. AMD’s Danny Moore (AI Tech Dir.) noted the Astera-AMD UALink work ensures GPUs can be deployed “at scale in open rack architectures” Nasdaq.

Astera’s stock has been volatile on recent AI infrastructure news. After surging on an earlier AMD/OpenAI deal – Citi analysts noted Astera’s shares “popped 10%” after that announcement Investopedia – the Oct 14 AMD-Oracle GPU deal triggered a sharp pullback Tipranks. The sell-off reflects renewed competition concerns: Morgan Stanley warned Nvidia’s NVLink could eventually “replace the traditional PCIe connection” between CPU and GPU, directly threatening Astera’s core business Gurufocus. Astera has countered by stressing open standards. Analyst Patrick Moorhead (Moor Insights) observes that “open standards are critical” for next-generation AI rack architectures Nasdaq, while Astera’s CEO Sanjay Gajendra emphasizes the need to “collaborate, standardize, and accelerate” innovation Nasdaq.

Financially, Astera remains strong. Its Aug 5 Q2 results beat estimates: revenue $191.93M vs. $172M expected, and EPS of $0.44 vs. $0.33 expected Marketbeat. Cash flow was robust, supporting the $1.07B cash on hand. Finviz The company’s networking products (retimers, switches) are in demand as AI datacenters scale. Astera guided Q3 revenue to $203–210M Finviz, implying continued double‑digit growth. (It expects EPS ~$0.38–0.39 for Q3 Marketbeat.) In the long run, BofA sees a $5B AI infrastructure market by 2030, and Astera aims to capitalize on that surge Finviz.

Analysts are divided on timing. Citi’s Atif Malik (Buy, $275 PT) remains enthusiastic, highlighting Astera’s role in open AI network ecosystems Finviz Finviz. Others are more cautious: Jefferies (Buy) raised its target to only $130, and a few firms have held or trimmed their ratings to Neutral/Hold, reflecting valuation risks Marketbeat. However, the average 12‑month target (~$187) suggests material upside from current levels Tipranks.

In context, the semiconductor/AI chip sector has been rallying (e.g. AMD jumped 24% on the OpenAI news Investopedia). Connectivity specialists like Astera trade on how these ecosystems evolve. With new partnerships (Arm, AMD, OCP Consortium) and its PCIe6 roadmap, Astera is positioning for the AI Infrastructure 2.0 transition. Investors will be watching its upcoming Nov 4 earnings for signs that growth can continue despite intensifying competition.

Sources: Astera Labs press releases and filings Nasdaq Finviz; market news (MarketBeat, TipRanks, GuruFocus) Tipranks Finviz Marketbeat; analyst reports (Citi, BofA) Finviz Tipranks; sector context (Investopedia) Investopedia Investopedia.

Stock Market Today

  • Gilead Sciences priced for upside after 38.5% one-year gain, DCF signals undervaluation
    January 11, 2026, 11:55 AM EST. GILD traded near $121.10, up 0.6% in 30 days and 38.5% over the past year. The stock's longer-term returns-56.0% over three years and 131.7% over five-frame questions about risk and upside as investors reassess pipelines, approvals and competitive pressures in biopharma. A valuation check assigns Gilead Sciences a 5 out of 6 score, then three methods show divergent views. A two-stage free cash flow to equity model yields an intrinsic value around $274.50 per share, implying the stock is about 55.9% undervalued vs $121.10. The P/E stands at 18.53x, modest versus some biotech peers, underscoring how growth expectations and risk shape multiples. Overall, the model suggests meaningful upside from current levels.
Nova Minerals (ASX:NVA) Stock Skyrockets on U.S. Critical Minerals Buzz – Gold Explorer’s 2025 Rally
Previous Story

Nova Minerals (ASX:NVA) Stock Skyrockets on U.S. Critical Minerals Buzz – Gold Explorer’s 2025 Rally

ASML Stock Soars on AI Mega-Deal as Q3 Earnings Loom – Key Facts and Outlook
Next Story

ASML Stock Soars on AI Mega-Deal as Q3 Earnings Loom – Key Facts and Outlook

Go toTop